Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events

Expert Opinion on Investigational Drugs

Volumn 19, Issue 12, 2010, Pages 1557-1567

  Tomasello, Salvatore Davide ^a   Angiolillo, Dominick J ^a   Goto, Shinya ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

PAR; platelet; thrombin; thrombosis

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; CLOPIDOGREL; E 5555; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; SCH 205831; SCH 602539; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBIN RECEPTOR ANTAGONIST; TRYPSIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; ATHEROSCLEROSIS; BINDING AFFINITY; BIOMECHANICS; BLEEDING; BRAIN ISCHEMIA; CLINICAL TRIAL; DRUG METABOLISM; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PROTEIN BINDING; PROTEINASE INHIBITION; REVASCULARIZATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANIMALS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; HUMANS; IMINES; LACTONES; PYRIDINES; RECEPTOR, PAR-1; THROMBOSIS; TREATMENT OUTCOME;

EID: 78649524025     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.521741     Document Type: Review

References (80)

1. American Heart Association. Heart disease and stroke statistics- 2006 update. American Heart Association, Dallas; 2006
2. WHO. Atlas of heart disease and stroke. World Health Organization, Geneva; 2004
3. Brass LF. Thrombin and platelet activation. Chest 2003;124:18S-25S
4. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94
5. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008;28:403-12
6. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006;99:1293-304
7. Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced Pselectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002;88:488-94
8. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002;8:247-52
9. Hagihara M, Higuchi A, Tamura N, et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol 2004;172:5297-303
10. Andersen H, Greenberg DL, Fujikawa K, et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999;96:11189-93
11. Ohlmann P, Eckly A, Freund M, et al. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood 2000;96:2134-9
12. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007;100:1261-75
13. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107:1591-8
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86
15. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403
16. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-19
17. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106
18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
19. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
20. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002;288:2411-20
21. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
22. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607-21
23. Leon C, Alex M, Klocke A, et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 2004;103:594-600
24. Van Der Meijden PE, Feijge M.A., Giesen PL, et al. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 2005;93:1128-36
25. Gurbel PA, Bliden KP, Guyer K, et al. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 2007;119:563-70
26. Bal Dit Sollier C, Mahe I, Berge N, et al. Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. Thromb Res 2003:111;19-27.
27. Angiolillo DJ, Capranzano P, Desai B, et al. Impact of P2Y12 inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res 2009;124:318-22
28. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J 2008;156:S3-9
29. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16
30. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008;336:195-8
31. Serebruany VL, Malinin AI, Ferguson JJ, et al. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol 2008;22(3):315-21
32. Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl Med 2007;357:2001-15
33. Wallentin L, Becker RC, Budaj A, et al.; for the PLATO investigators. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
34. Coughlin SR. Protease-activated receptors in heamostasis, thrombosis and vascular biology. J Thromb Heamost 2005;3:1800-14
35. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002;100:148-52
36. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004;84:579-621
37. Shah R. Protease-activated receptors in cardiovascular health and diseases. Am Heart J 2009;157:253-62
38. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103:879-87
39. Steinhoff M, Buddenkotte J, Shpacovitch V, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005;26:1-43
40. Henriksen RA, Hanks VK. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Arterioscler Thromb Vasc Biol 2002;22:861-6
41. Covic L, Singh C, Smith H, Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky- Pudlak syndrome. Thromb Haemost 2002;87:722-7
42. Lova P, Campus F, Lombardi R, et al. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the Gi-independent activation of platelet Rap1B by thrombin. J Biol Chem 2004;279:25299-306
43. Smith CC, Wilson AP, Prichard BN, Betteridge DJ. Stimulus-induced release of endogenous catecholamines from human washed platelets. Clin Sci (Lond) 1986;70:495-500
44. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4
45. Stenberg PE, McEver RP, Shuman M.A., et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880-6
46. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91:2645-57
47. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in Galphaq-deficient mice. Nature 1997;389:183-6
48. Andersen H, Greenberg DL, Fujikawa K, et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999;96:11189-93
49. Goldsack NR, Chambers RC, Dabbagh K, Laurent GJ. Thrombin. Int J Biochem Cell Biol 1998;30:641-6
50. Faruqi TR, Weiss EJ, Shapiro MJ, et al. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000;275:19728-34
51. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006;114:1070-7
52. The TRACER Exective and Steering Committees. The Thrombin Receptor
53. Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial: study design and rationale. Am Heart J 2009;158:327-34
54. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 P)-TIMI 50 trial. Am Heart J 2009;158:335-41
55. Safety and tolerability of E5555 and its effects on markers of intravascular inflammation in subjects with coronary artery disease. Bethesda, MD: US National Institutes of Health, 2006. Available from:http://www. clinicaltrials. gov/ct2/show/NCT00312052. [Last accessed 7 September 2010]
56. Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL; on Behalf of the J-LANCELOT (Japanese-Lesson from Antagonizing the cellular Effect of Thrombin) investigators. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J. 2010 Aug 30 [Epub ahead of print]
57. Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherothromosis: therapeutic potential of vorapaxar and e-5555. Drugs 2010;70(14):1771-83
58. Chackalamannil S, Davies RJ, Asberom T, et al. A highly efficient total synthesis of (+)-himbacine. J Am Chem Soc 1996;118:9812-13
59. Doller D, Chackalamannil S, Czarniecki M, et al. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett 1999;9:901-6
60. Oestreich J. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Invest Drugs 2009;10:988-96
61. Chintala MS, Chiu PJ, Bernadino V, et al. Disparate effects of thrombin receptor activating peptide on platelets and peripheral vasculature in rats. Eur J Pharmacol 1998;349:237-43
62. Chackalamannil S, Xia Y, Greenlee WJ, et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 2005;48:5884-7
63. Chintala M, Ahn H, Foster C, et al. Antithrombotic effects of SCH 205831: a potent, selective and orally active antagonist of the PAR-1 thrombin receptor. J Thromb Haemost 2005;3:abstract OR286
64. Chintala M, Kurowski S, Vemulapalli S, et al. Efficacy of SCH 602539, a selective thrombin receptor antagonist alone and in combination with cangrelor in a Folts model of thrombosis in anesthetized monkeys. Eur Heart J 2007;28(Suppl 1):, abstract 188
65. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008;51:3061-4
66. Chintala M, Shimizu K, Ogawa M, et al. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci 2008;108:433-8
67. Kosoglou T, Reyderman L, Fales RR, et al. Pharmacodynamics and pharmacokinetics of a novel protease-activated receptor (PAR-1) antagonist SCH 530348. Circulation 2005;112(Suppl II):II-32
68. Kosoglou T, Tiessen R, Van Vliet AA, et al. Safety and tolerability of SCH 530348, a novel antiplatelet agent, after single and multiple oral dosing in healthy subjects. Eur Heart J 2008;29(Suppl 201):P1340
69. Reyderman L, Kosoglou T, Kasserra C, et al. Lack of ethnic differences in the pharmacodynamics (PD) and pharmacokinetics (PK) of SCH 530348, a novel oral antiplatelet agent, in Japanese and Caucasian subjects. Clin Pharmacol Ther 2009;85(Suppl S21):PI-41
70. Kosoglou T, Reyderman L, Kasserra C, et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clin Pharmacol Ther 2008;83(Suppl 1):S55
71. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled Phase II study. Lancet 2009;373:919-28
72. Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segent elevation acute coronary syndrome. J Atheroscler Thromb 2010;17(2):156-64
73. Shinihara Y, Goto S, Doi M, Jensen P. Safety of the Novel Protese-Activated Receptor-1 Antagonist Vorapaxar in Japanese Patients with A History of Ischemic Stroke. J Stroke Cererovasc Dis 2010; In press
74. Matsuoka T, Kogushi M, Kawata T, et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury [abstract]. JACC 2004;43:68A
75. Kogushi M, Yokohama H, Kitamura S, Hishinuma I. Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro. J Thromb Haemost 2007;5:P-M-059
76. Kai Y, Hirano K, Maeda Y, et al. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke 2007;38:3259-65
77. Serebruany VL, Kogushi M, Dastros-Pitei D, et al. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009;102:111-19
78. Takeuchi M, Kageyama M, Kitamura S, et al. Pharmacodinamics and safety of a novel protease activated receptor-1 antagonist E5555 in healthy volunteers. Eur Heart J 2007;28(Suppl):14
79. Kato Y, Kita Y, Hirasawa-Taniyama T, et al. Inhibition of arterial thrombosis by a protease activeted receptor 1 antagonist, FR171113 in the guinea pig. Eur J Pharmacol 2003;473:163-9
80. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010;31:17-28